NEWS RELEASE - PRESSEMITTEILUNG

Acino's rivastigmine patch launched in Germany Aesch, April 16, 2013, 17.30 hrs - Acino announced today that its rivastigmine patch has been launched in Germany as the first generic alternative to the branded product. The once-daily transdermal system is indicated for the symptomatic treatment of mild to moderate forms of Alzheimer dementia, one of the most common diseases affecting the growing elderly population in developed nations.

The rivastigmine patch developed by Acino received EU approval in March 2013 and is being out-licensed for commercialization. In the first launch country Germany, Acino is partnering with the leading generics company Betapharm who introduced the product on April 15, 2013. Additional out-licensing negotiations are ongoing with pharmaceutical partners worldwide. Acino manufactures the rivastigmine patch at its state-of-the-art site in Miesbach (Germany), featuring the most modern facilities for transdermal systems, and supplies license takers with finished product. Subject to the successful completion of ongoing national registrations, Acino anticipates a roll-out of its new product across Europe during 2013.
Acino is a technology leader for transdermal products and the second largest patch producer in Europe. The successful development and launch of transdermal rivastigmine underpins the ability of Acino to advance technologically sophisticated pharmaceuticals to market readiness.

Acino - Delivering Health

Acino (SIX: ACIN), a Swiss-based pharmaceutical company, develops, manufactures and internationally markets well-proven and innovative pharmaceuticals in novel drug delivery forms. Acino is a leader in advanced drug delivery technologies with a focus on modified release oral forms, oral dispersible forms, transdermal systems and extended release parenterals, for which it also holds patents. As a partner of pharmaceutical companies worldwide, Acino supplies finished in-house developed products and/or provides customized one-stop solutions from product development and registration to contract manufacturing, packaging and logistics. Under the brand "Acino Switzerland", Acino markets Swiss-quality medicines in up and coming economies, currently 80 countries in the Middle East, Africa, Latin America and Asia. The Acino Group, headquartered in Aesch BL, has 836 employees and generated annual revenues of EUR 257 million in 2012.

Contact Calendar

Robert Schmid

Media & Investor Relations Phone +41 61 338 61 15 robert.schmid@acino-pharma.com www.acino-pharma.com

30.7.2013 Half-year Report as of June 30, 2013

Acino Holding AG Dornacherstr. 114

CH-4147 Aesch

Phone +41 61 338 60 00

Fax +41 61 338 60 80 www.acino-pharma.com

distributed by